Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.37 |
| ▸ | MPEG1 | Q2M385 | 4/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CDC25A | P30304 | 6/20 | 0.37 |
| ▸ | CDC25B | P30305 | 6/20 | 0.37 |
| ▸ | CDC25C | P30307 | 5/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11156027 | 0.70 | ACHE (0.37) | ALOX5MPEG1ACHEBACE1CDC25A | |
| SCHEMBL9264130 | 0.69 | ACHE (0.40) | ALOX5MPEG1ACHEBACE1CDC25A | |
| SCHEMBL8780203 | 0.69 | ACHE (0.40) | ALOX5MPEG1ACHEBACE1CDC25A | |
| SCHEMBL8914982 | 0.67 | TDP1 (0.38) | PTPN1ALOX5ACHEBACE1CDC25B | |
| SCHEMBL6525048 | 0.66 | — | — | |
| SCHEMBL14065928 | 0.66 | ACHE (0.47) | PTPN1ALOX5MPEG1ACHEBACE1 | |
| SCHEMBL14065926 | 0.66 | ACHE (0.47) | PTPN1ALOX5MPEG1ACHEBACE1 | |
| SCHEMBL6544586 | 0.65 | ACHE (0.47) | PTPN1ALOX5ACHEBACE1CDC25A | |
| SCHEMBL82554 | 0.65 | CDC25A (0.69) | ALOX5CDC25ACDC25BCDC25C | |
| SCHEMBL11157415 | 0.64 | CTRC (0.33) | ALOX5ACHEBACE1CDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531616-B2 | Contacting lactone compound with an oxalate in presence of a base and a solvent to form an intermediate mixture; reacting with a formaldehyde derivative to form a product mixture; isolating alpha - substituted hydrocarbylidene lactones | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-03-11 | — | — | US | disclosed |
| US-20020143195-A1 | Process for the preparation of a-methylenelactones and a-substituted hydrocarbylidene lactones | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143195-A1 | Process for the preparation of a-methylenelactones and a-substituted hydrocarbylidene lactones | ESD, ODC1, DDT | PTPN1 4220/4885ALOX5 504/4885MPEG1 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.